Campbell’s AI Medical Claims Adjudication Patent Refused by CIPO
Stanley Victor Campbell, represented by Deeth Williams Wall LLP, sought patent protection in Canada for a machine-based system automating medical diagnostic code identification, accumulation, analysis, and insurance claim adjudication. The Commissioner, adopting the Patent Appeal Board’s recommendation, refused all 27 claims on dual grounds: subject-matter outside the statutory definition of invention and matter prohibited under subsection 27(8) of the Patent Act.
All 27 Claims Refused: Dual Unpatentability Grounds Under Canadian Patent Act
Stanley Victor Campbell filed Canadian patent application CA2816107A1 covering a system and method for machine-based medical diagnostic code identification, accumulation, analysis, and automatic insurance claim adjudication. The application was examined by the Canadian Intellectual Property Office and ultimately reviewed by the Patent Appeal Board before reaching the Commissioner of Patents for a final determination, which was issued on 18 October 2024.
The Commissioner accepted the Patent Appeal Board’s recommendation in full and refused to grant the patent under section 40 of the Patent Act. Two independent grounds supported the refusal: claims 1 to 27 were found to encompass subject-matter falling outside the statutory definition of ‘invention’ under section 2 of the Act, and those same claims defined subject-matter prohibited by subsection 27(8), which bars patents directed solely to abstract methods or disembodied schemes. The applicant now has six months under section 41 to appeal to the Federal Court of Canada.
The dual-ground refusal is consistent with CIPO’s increasingly rigorous application of the ‘actual invention’ framework to AI-assisted and software-implemented health informatics claims. Without sight of the full prosecution history, it is unclear whether claim amendments were proposed during the Board proceedings that might have addressed the section 2 objection. The public record is silent on whether Campbell intends to pursue the Federal Court appeal, which would likely turn on the appropriate characterisation of the claimed invention.
Filing to Unpatentable in 0 days
Case closed 18 October 2024 at the CIPO Commissioner level
Commissioner refuses CA2816107A1: what the dual-ground ruling means
Section 2 + s. 27(8): two independent bars to patentability
Canadian patent law requires that a claimed invention fall within the statutory definition in section 2 (art, process, machine, manufacture, or composition of matter). Subsection 27(8) separately prohibits patents on abstract mental steps or schemes. A refusal on both grounds simultaneously means no single amendment strategy could save the application without a fundamental reconceptualisation of what is being claimed.
Dual statutory barSix-month window to challenge refusal at Federal Court
Under section 41 of the Patent Act, Campbell has six months from the Commissioner’s decision to file an appeal with the Federal Court of Canada. The Federal Court reviews CIPO Commissioner decisions on a correctness or reasonableness standard depending on the legal question at issue. If no appeal is filed, the application is permanently abandoned and the invention enters the public domain without patent protection.
Federal Court appeal availableRefusal confirms CIPO’s strict approach to AI health informatics claims
The Commissioner’s full adoption of the Patent Appeal Board recommendation — without modification — signals a consistent institutional position on software-implemented medical diagnostic and claims-processing systems. Applicants in the health informatics space should expect examiners to probe whether claims define a concrete technical improvement or merely automate an abstract cognitive process, consistent with CIPO’s 2020 Subject-Matter Eligibility Guidance.
Consistent CIPO policyHealth AI developers face elevated prosecution risk in Canada
Competitors and licensees in the AI-driven medical billing and claims adjudication space receive indirect benefit from this refusal: the disclosed system remains unprotected in Canada. However, developers of analogous technology should not assume freedom to operate globally — equivalent applications may exist in other jurisdictions. Canadian prosecution strategy for health AI should front-load claim drafting to anchor all claims to a specific technical effect or hardware implementation.
Canadian health AI riskFull party and counsel information
| Role | Name | Type | Detail |
|---|---|---|---|
| Plaintiff | Stanley Victor Campbell | Individual | Independent inventor — applicant for CA2816107A1 covering AI-driven medical claims adjudicationSearch in Eureka ↗ |
| Defendant | Defendant | Individual | Canadian Intellectual Property Office — federal patent granting authority; represented by the Commissioner of PatentsSearch in Eureka ↗ |
| Plaintiff law firm | Deeth Williams Wall LLP | Law Firm | Representing Stanley Victor CampbellSearch in Eureka ↗ |
| Presiding judge | Judge N/A | Judge | CIPOSearch in Eureka ↗ |
Official order — verbatim text
The Commissioner’s decision adopts the Patent Appeal Board’s recommendation verbatim, refusing all 27 claims on two concurrent statutory grounds. The reference to section 2 suggests the Board characterised the ‘actual invention’ as an abstract method of organising information rather than a patentable art or process. The additional subsection 27(8) finding — directed at prohibited subject-matter — reinforces that characterisation. Together, these findings leave no room for partial allowance; the entire claim set fails. The applicant’s only recourse within the Canadian system is a Federal Court appeal under section 41.
CA2816107A1 — Machine-Based Medical Diagnostic Code & Claims Adjudication System
CA2816107A1 is a Canadian patent application directed to a system and method for automating the end-to-end pipeline of medical diagnostic code identification, accumulation, analysis, and insurance claim adjudication. The application number format indicates a national phase entry or direct Canadian filing, with the ‘2816107’ series consistent with applications prosecuted through the 2010s. The claimed invention sits at the intersection of health informatics, natural language or code processing, and automated decision-making — a domain that raises subject-matter eligibility questions in multiple jurisdictions.
Strategically, a granted patent on this system would have provided meaningful protection over AI-driven medical billing automation — a rapidly growing sector as healthcare providers adopt machine-learning tools for revenue cycle management. The refusal means the disclosed architecture is now publicly accessible without a Canadian patent barrier, but competitors should verify whether equivalent or related applications exist in the US, EP, or other markets before assuming full freedom to operate. The case also underscores the importance of drafting claims that explicitly tie automated diagnostic code analysis to a specific technical improvement in computing performance or data processing, rather than framing the invention purely in terms of its administrative or commercial outcome.
Should you run an FTO against CA2816107A1?
Product and R&D teams building AI-driven medical coding, billing automation, or insurance claims adjudication tools in Canada should note that CA2816107A1 has been refused — meaning no patent rights arise from this specific application in Canada. However, a complete freedom-to-operate assessment must also check: (1) whether Campbell holds any granted Canadian patents in related subject-matter; (2) whether equivalent applications were filed in the US, Europe, or other jurisdictions; and (3) whether third-party patents cover overlapping claim scope in your target markets.
PatSnap Eureka’s FTO Search Agent can rapidly map the patent landscape around machine-based medical diagnostic coding and claims adjudication systems, identifying live patent families, pending applications, and expired rights across jurisdictions. For health AI developers, this analysis should be updated regularly as the Federal Court appeal window remains open and as CIPO examination practice continues to evolve under updated subject-matter eligibility guidelines.
Run a freedom-to-operate analysis on CA2816107A1 to assess your product’s exposure
Run FTO in Eureka →Similar CIPO Refusals: AI & Software-Implemented Health Informatics Patents
Cases where CIPO or the Patent Appeal Board refused AI-assisted medical and health informatics patent applications on section 2 or subsection 27(8) grounds.
What this case signals for the Canadian health AI patent landscape
CIPO’s dual-ground refusal of CA2816107A1 reinforces a clear pattern: abstract AI-assisted medical processing systems face a high patentability bar in Canada.
Anchor health AI claims to a concrete technical improvement, not a result
Canadian patent practice post-Choueifaty requires claims to be assessed for their ‘actual invention.’ For AI-driven medical diagnostic or billing systems, applicants must ensure independent claims recite a specific technical mechanism — not merely the outcome of automated processing — to survive a section 2 objection.
Dual-ground refusals are harder to reverse on appeal than single-ground rulings
When both section 2 and subsection 27(8) bars are found, a Federal Court appeal must displace both findings. This increases litigation cost and uncertainty. Health informatics applicants should consider whether prosecution-stage claim amendments can address both objections before a Board recommendation issues.
Campbell v Defendant — key questions answered
The Commissioner refused CA2816107A1 because all 27 claims were found to encompass subject-matter outside the statutory definition of ‘invention’ under section 2 of the Patent Act and to define subject-matter prohibited by subsection 27(8). The Patent Appeal Board reached the same conclusion and the Commissioner adopted its recommendation in full.
Yes. Under section 41 of the Patent Act, Campbell has six months from the Commissioner’s decision (issued 18 October 2024) to appeal to the Federal Court of Canada. The Federal Court has jurisdiction to review both the legal characterisation of the invention and the application of the patentability criteria.
Subsection 27(8) of the Patent Act prohibits the granting of a patent for any mere scientific principle or abstract theorem. CIPO and the Patent Appeal Board apply this provision to refuse claims that, in substance, cover a disembodied method, mental process, or abstract scheme without a concrete physical or technical manifestation — a standard particularly relevant to AI and software-implemented inventions.
The refusal means no patent rights arise from CA2816107A1 in Canada. However, freedom to operate in the medical diagnostic coding and claims adjudication space requires a broader clearance search — including any granted Campbell patents, related family members in other jurisdictions, and third-party patents covering overlapping technology — before a definitive FTO conclusion can be drawn.
The Patent Appeal Board is a body within CIPO that reviews final action rejections by patent examiners and makes a recommendation to the Commissioner of Patents. The Commissioner is not bound by the recommendation but, as in this case, frequently adopts it. The Board’s review is the last internal step before an applicant can seek Federal Court review under section 41 of the Patent Act.
PatSnap Eureka searches patents and litigation data to answer instantly.